Slides on SGLT2 Inhibitor Therapy in Type 2 Diabetes

Learn about the role of SGLT-2 inhibitors in treating type 2 diabetes.
Anne Peters, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.96 MB
Released: December 10, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

This activity is supported by an independent educational grant from
Boehringer Ingelheim Pharmaceuticals, Inc.

Related Content

Expert commentary on the use of GLP-1 receptor agonists in the management of patients with type 2 diabetes

person default Arthi Thirumalai, MBBS Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: December 18, 2020 Expired: December 17, 2021

Get patient-specific guidance on T2D treatment options and insights on managing CVD and CKD risk, from Clinical Care Options (CCO)

Anne Peters, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Released: December 10, 2020 Expired: December 9, 2021

Enter type 2 diabetes patient characteristics in this online CCO tool and compare your treatment plan with those of 5 experts

Martin J. Abrahamson, MD, FACP Zachary T. Bloomgarden, MD, MACE Anne Peters, MD Richard E. Pratley, MD Robert S. Zimmerman, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: December 9, 2020 Expired: December 8, 2021

Vanita R. Aroda, MD, and Arthi Thirumalai, MBBS: from Endocrine Society and CCO. CME Webinar on GLP-1 RAs in T2D, including latest ADA and AACE guidelines

person default Vanita R. Aroda, MD person default Arthi Thirumalai, MBBS Physicians: maximum of 1.0 AMA PRA Category 1 Credit ABIM MOC: maximum of 1.0 Medical Knowledge MOC point(s) Registered Nurses: 1.0 Nursing contact hour Released: December 4, 2020 Expired: December 31, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue